23rd International AIDS Conference (AIDS 2020): second reports
28 August 2020. Related: Conference reports.
World AIDS 23 Virtual 2020
Capsid inhibitor lenacapavir (GS-6207) allows for 6-monthly dosing
28 August 2020. Related: Conference reports, Antiretrovirals.
Weight gain with integrase inhibitors and TAF: three reports from AIDS 2020
28 August 2020. Related: Conference reports, Side effects.
Dolutegravir non-inferior to efavirenz at week 96 in the NAMSAL study but associated with substantial weight gain
28 August 2020. Related: Conference reports, Treatment strategies.
Switching from efavirenz- to dolutegravir-based ART second-line achieved good rates of suppression: first results from the VISEND study
28 August 2020. Related: Conference reports, Treatment strategies.
Paediatric dolutegravir dosing at AIDS 2020
28 August 2020. Related: Conference reports, Paediatric care.
COVID-19 outcomes in HIV positive people in two large US cohorts
28 August 2020. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
AIDS 2020: virtual content now available free and on-demand
28 August 2020. Related: Conference reports, Other news.
Pathways to an HIV cure: online presentations
28 August 2020. Related: Conference reports, Cure-related research.
AIDS 2020 online: introduction
22 July 2020. Related: Conference reports.
AIDS 2020: Navigating the website
22 July 2020. Related: Conference reports.
Neural tube defects in two of 1000 conception exposures with dolutegravir: reassuring update from Tsepamo study
22 July 2020. Related: Conference reports, Pregnancy.
Dolutegravir associated with weight gain in African ART programmes: findings from AFRICOS
22 July 2020. Related: Conference reports, Side effects.
ADVANCE 96-week results: dolutegravir weight gain continues, especially in women and when used with TAF – no evidence of a plateau
22 July 2020. Related: Conference reports, Antiretrovirals.
Pregnancy meta-analysis: dolutegravir- versus efavirenz-based ART
22 July 2020. Related: Conference reports, Pregnancy.
Long-acting cabotegravir injections are effective as HIV PrEP in gay men and transgender women: results from HPTN 083
22 July 2020. Related: Conference reports, HIV prevention and transmission.
Case report of short-term HIV remission from adding oral nicotinamide to intensified ART
22 July 2020. Related: Conference reports, Cure-related research.
New HIV remission case report at AIDS 2020: full report
22 July 2020. Related: Conference reports, Cure-related research.